These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 12754630)

  • 1. Images in pathology. Morphologic features of response to Gleevec (Imatinib) treatment of GIST.
    Colecchia M; Diment J
    Int J Surg Pathol; 2003 Apr; 11(2):119. PubMed ID: 12754630
    [No Abstract]   [Full Text] [Related]  

  • 2. F-18 FDG PET imaging in gastrointestinal stromal tumor.
    Reddy MP; Reddy P; Lilien DL
    Clin Nucl Med; 2003 Aug; 28(8):677-9. PubMed ID: 12897659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CT scan is not everything in the evaluation of a patient with gastrointestinal tumors (GIST) under imatinib therapy.
    Wang CM; Fu H; Zhao GF; Wang J; Shi YQ
    Pathol Oncol Res; 2012 Oct; 18(4):1095-7. PubMed ID: 21927980
    [No Abstract]   [Full Text] [Related]  

  • 4. Challenges in oncology. Case 4. Response of metastatic gastrointestinal stromal tumor including CNS involvement to imatinib mesylate (STI-571).
    Brooks BJ; Bani JC; Fletcher CD; Demeteri GD
    J Clin Oncol; 2002 Feb; 20(3):870-2. PubMed ID: 11821475
    [No Abstract]   [Full Text] [Related]  

  • 5. [Targeted treatment of cancers with imatinib mesylate (STI571, Gleevec): results of Asco 2002].
    Ray-Coquard I; Blay JY
    Bull Cancer; 2002 Jun; 89(6):567-9. PubMed ID: 12135855
    [No Abstract]   [Full Text] [Related]  

  • 6. Successful treatment with sunitinib in a young patient with metastatic gastrointestinal stromal tumor after failure on adjuvant imatinib.
    Kapoor R; Khosla D; Kumar P; Kumar N; Bera A
    J Cancer Res Ther; 2011; 7(4):491-3. PubMed ID: 22269418
    [No Abstract]   [Full Text] [Related]  

  • 7. [Chemotherapy and target-therapy of gastrointestinal tumors call for development of pathology].
    Shen L
    Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):438-9. PubMed ID: 17845753
    [No Abstract]   [Full Text] [Related]  

  • 8. GIST: an update.
    Rosai J
    Int J Surg Pathol; 2003 Jul; 11(3):177-86. PubMed ID: 12894349
    [No Abstract]   [Full Text] [Related]  

  • 9. Gastrointestinal stromal tumours: etiology, pathology and clinical management.
    Blackstein ME; Dubé P; Fletcher JA; Keller OR; Knowling M; Létourneau R; Morris D; Riddell R; Rorke S; Swallow CJ;
    Can J Gastroenterol; 2004 Sep; 18 Suppl B():3B-8B. PubMed ID: 15457300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST).
    Hochhaus A
    Ann Hematol; 2004; 83 Suppl 1():S65-6. PubMed ID: 15124676
    [No Abstract]   [Full Text] [Related]  

  • 11. [Gastrointestinal stromal tumor (GIST)--tyrosine kinase inhibitors].
    Nishida T; Yoshidome K; Tori M
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():452-6. PubMed ID: 23513883
    [No Abstract]   [Full Text] [Related]  

  • 12. [Molecular and histologic characteristics of secondary imatinib-resistant gastrointestinal stromal tumors].
    Zheng S; Jia J; Pan YL; Tao DY; Lu HS
    Zhonghua Bing Li Xue Za Zhi; 2013 Jan; 42(1):42-3. PubMed ID: 23611272
    [No Abstract]   [Full Text] [Related]  

  • 13. Imatinib mesylate therapy in patients with gastrointestinal stromal tumors and impaired liver function.
    Bauer S; Hagen V; Pielken HJ; Bojko P; Seeber S; Schütte J
    Anticancer Drugs; 2002 Sep; 13(8):847-9. PubMed ID: 12394270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.
    Dagher R; Cohen M; Williams G; Rothmann M; Gobburu J; Robbie G; Rahman A; Chen G; Staten A; Griebel D; Pazdur R
    Clin Cancer Res; 2002 Oct; 8(10):3034-8. PubMed ID: 12374669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [FDG-PET and CT in gastrointestinal stromal tumor treated with imatinib].
    Eigtved AI; Berthelsen AK; Kinnander C; Krarup-Hansen A
    Ugeskr Laeger; 2003 Sep; 165(37):3507-9. PubMed ID: 14531350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib mesylate: a molecularly targeted therapy for gastrointestinal stromal tumors.
    Eisenberg BL
    Oncology (Williston Park); 2003 Nov; 17(11):1615-20; discussion 1620, 1623, 1626 passim. PubMed ID: 14682111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced or metastatic gastrointestinal stromal tumors: systemic treatment options.
    Caram MV; Schuetze SM
    J Surg Oncol; 2011 Dec; 104(8):888-95. PubMed ID: 22069173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of pharmacokinetic studies for patients with gastrointestinal stromal tumors.
    De Giorgi U
    Future Oncol; 2013 Nov; 9(11):1675-7. PubMed ID: 23862700
    [No Abstract]   [Full Text] [Related]  

  • 19. [Gain-of-function mutation of c-kit gene and molecular target therapy in GISTs].
    Hirota S
    Nihon Shokakibyo Gakkai Zasshi; 2003 Jan; 100(1):13-20. PubMed ID: 12601923
    [No Abstract]   [Full Text] [Related]  

  • 20. The clinical characteristics and the role of surgery and imatinib treatment in patients with liver metastases from c-Kit positive gastrointestinal stromal tumors (GIST).
    Rutkowski P; Nyckowski P; Grzesiakowska U; Nowecki ZI; Nasierowska-Guttmejer A; Pienkowski A; Dudek K; Krawczyk M; Ruka W
    Neoplasma; 2003; 50(6):438-42. PubMed ID: 14689066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.